Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.

PHASE3CompletedINTERVENTIONAL
Enrollment

375

Participants

Timeline

Start Date

December 8, 2020

Primary Completion Date

August 23, 2022

Study Completion Date

August 23, 2022

Conditions
OverweightObesityDiabetes Mellitus, Type 2
Interventions
DRUG

Semaglutide

Semaglutide administered subcutaneously (s.c., under the skin) as well as diet and physical activity counselling for 44 weeks. Doses gradually increased to 2.4 mg

DRUG

Placebo (semaglutide)

Semaglutide placebo administered s.c. as an adjunct to a reduced-calorie diet and increased physical activity regimen for 44 weeks

Trial Locations (29)

16499

Ajou University Hospital, Gyeonggi-do

100853

Chinese People's Liberation Army General Hospital-Endocrinology, Beijing

101200

Beijing Pinggu Hospital-Endocrinology, Beijing

130061

The First Bethune hospital of Jilin University-Endocrinology, Changchun

200040

Huashan Hospital Fudan University-Endocrinology, Shanghai

200072

Shanghai Tenth People's Hospital (Tenth People's of Tongji University)-Endocrinology, Shanghai

200240

Shanghai Fifth People's Hospital-Endocrinology, Shanghai

200336

Tongren Hospital Shanghai Jiao Tong University School of Medicine, Shanghai

201200

Shanghai Pudong New Area People's Hospital-Endocrinology, Shanghai

210011

The Second Affiliated Hospital of Nanjing Medical University-Endocrinology, Nanjing

210029

Jiangsu Province Hospital-Endocrinology, Nanjing

212001

The Affiliated Hospital of Jiangsu University-Endocrinology, Zhenjiang

213003

Changzhou No.2 People's Hospital, Yanghu Branch, Changzhou

215006

The First Affiliated Hospital of Soochow University, Suzhou

250013

Jinan Central Hospital Affiliated to Shandong University, Jinan

300052

General Hospital of Tianjin Medical University-Endocrinology, Tianjin

300211

The Second Hospital of Tianjin Medical University, Tianjin

350001

Fujian Medical University Union Hospital-Endocrinology, Fuzhou

404000

Chongqing University Three Gorges Hospital, Chongqing

650101

The Second Affiliated Hospital of Kunming Medical University, Kunming

74935-530

Instituto de Ciências Farmacêuticas de Estudos e Pesquisas, Aparecida de Goiânia

01228-200

CPCLIN - Centro de Pesquisas Clínicas, São Paulo

061000

Cangzhou People's Hospital, Cangzhou

053000

Harrison International Peace Hospital-Endocrinology, Hengshui

050000

The Second Hospital of Hebei Medical University-Endocrinology, Shijiazhuang

010020

Inner Mongolia People's Hospital-Endocrinology, Hohhot

010050

The affiliated Hospital of Inner Mongolia Medical University-Endocrinology, Hohhot

Unknown

Prince of Wales Hospital, Shatin, New Territories

03080

Seoul National University Hospital, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY